Truist Financial Corp Makes New $257,000 Investment in Henry Schein, Inc. (NASDAQ:HSIC)

Truist Financial Corp bought a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,710 shares of the company’s stock, valued at approximately $257,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Clarkston Capital Partners LLC increased its position in Henry Schein by 5.4% during the third quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company’s stock valued at $101,900,000 after acquiring an additional 71,560 shares during the last quarter. Nuance Investments LLC grew its stake in shares of Henry Schein by 22.3% during the 3rd quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock valued at $166,072,000 after purchasing an additional 414,748 shares during the period. Olstein Capital Management L.P. increased its position in shares of Henry Schein by 17.2% during the 4th quarter. Olstein Capital Management L.P. now owns 109,000 shares of the company’s stock valued at $7,543,000 after purchasing an additional 16,000 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Henry Schein in the 3rd quarter worth approximately $515,000. Finally, Equitable Trust Co. purchased a new position in shares of Henry Schein in the fourth quarter worth approximately $417,000. 96.62% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on HSIC. StockNews.com raised shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. UBS Group reduced their price objective on Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research note on Wednesday, February 26th. Barrington Research reiterated an “outperform” rating and set a $90.00 target price on shares of Henry Schein in a research report on Wednesday, February 26th. Jefferies Financial Group boosted their price target on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Finally, Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $69.00 to $84.00 in a research note on Monday, January 6th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Henry Schein has an average rating of “Moderate Buy” and an average price target of $81.10.

Henry Schein Stock Performance

NASDAQ:HSIC opened at $71.46 on Thursday. The stock has a 50-day moving average price of $74.42 and a 200 day moving average price of $72.51. The stock has a market capitalization of $8.87 billion, a P/E ratio of 29.41, a P/E/G ratio of 2.13 and a beta of 0.91. Henry Schein, Inc. has a 12-month low of $63.67 and a 12-month high of $82.49. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share for the quarter, missing the consensus estimate of $1.23 by ($0.04). The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.66 earnings per share. Equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.